Boston Scientific Corporation $BSX Shares Acquired by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund boosted its position in Boston Scientific Corporation (NYSE:BSX) by 0.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 127,839 shares of the medical equipment provider’s stock after acquiring an additional 1,200 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Boston Scientific were worth $13,731,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC increased its position in shares of Boston Scientific by 6.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 40,748 shares of the medical equipment provider’s stock valued at $4,377,000 after purchasing an additional 2,293 shares during the last quarter. Welch Group LLC lifted its position in shares of Boston Scientific by 3.5% during the 2nd quarter. Welch Group LLC now owns 4,641 shares of the medical equipment provider’s stock worth $498,000 after purchasing an additional 159 shares during the last quarter. Clarendon Private LLC grew its stake in shares of Boston Scientific by 11.5% during the second quarter. Clarendon Private LLC now owns 10,046 shares of the medical equipment provider’s stock worth $1,079,000 after purchasing an additional 1,037 shares in the last quarter. CWM LLC increased its holdings in Boston Scientific by 36.9% in the second quarter. CWM LLC now owns 51,316 shares of the medical equipment provider’s stock valued at $5,512,000 after buying an additional 13,840 shares during the last quarter. Finally, OFI Invest Asset Management increased its holdings in Boston Scientific by 34.9% in the second quarter. OFI Invest Asset Management now owns 12,817 shares of the medical equipment provider’s stock valued at $1,377,000 after buying an additional 3,317 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $18,659,923.46. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 1.9%

BSX opened at $95.41 on Monday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The business’s 50 day moving average is $101.98 and its two-hundred day moving average is $101.87. The firm has a market cap of $141.38 billion, a price-to-earnings ratio of 56.79, a price-to-earnings-growth ratio of 2.30 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the firm posted $0.62 earnings per share. The company’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of recent analyst reports. Leerink Partnrs raised Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Canaccord Genuity Group boosted their target price on Boston Scientific from $131.00 to $132.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Finally, UBS Group boosted their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $120.71.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.